Impact of Port-A-Cath device management in cancer patients with candidaemia.
This study investigated the impact of management of a totally implantable central venous access port device, Port-A-Cath (Smith Medical, St. Paul, MN, USA), on the outcome of 98 cancer patients with candidaemia. Port-A-Cath retention was found to be significantly associated with poorer outcome, independent of other significant adverse factors [breakthrough candidaemia, Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥ 21, and worse Eastern Cooperative Oncology Group (ECOG) performance score (3-4)]. However, retention of Port-A-Cath devices could be considered in patients who do not have definite catheter-related candidaemia, are not using total parenteral nutrition, do not have poor ECOG performance scores or APACHE II scores, and do not have septic shock.
Division of Haematology and Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Y-C
YC
Lai
L-J
LJ
Huang
T-L
TL
Chen
Y-W
YW
Yang
L-T
LT
Hsiao
H-W
HW
Teng
C-P
CP
Fung
T-J
TJ
Chiou
C-H
CH
Tzeng
C-Y
CY
Liu
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058387:Candidemia / Q000628:therapy*; D055499:Catheter-Related Infections / Q000453:epidemiology*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D017053:Infection Control / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014481:United States; D062666:Vascular Access Devices / Q000382:microbiology*